Next Article in Journal
Antibody Responses to Marburg Virus in Egyptian Rousette Bats and Their Role in Protection against Infection
Previous Article in Journal
Nonstructural Proteins of Alphavirus—Potential Targets for Drug Development
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessArticle
Viruses 2018, 10(2), 72; https://doi.org/10.3390/v10020072

Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models

1
Department of Biomedical Sciences, College of Medicine, Korea University Guro Hospital, Seoul 08308, Korea
2
Department of Tropical Medicine, Medical Microbiology and Pharmacology, Pacific Center for Emerging Infectious Diseases Research, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA
These two authors contributed equally to this work.
*
Authors to whom correspondence should be addressed.
Received: 3 January 2018 / Revised: 29 January 2018 / Accepted: 8 February 2018 / Published: 9 February 2018
(This article belongs to the Section Antivirals & Vaccines)
View Full-Text   |   Download PDF [3256 KB, uploaded 9 February 2018]   |  

Abstract

Zika virus (ZIKV) has recently emerged as a new public health threat. ZIKV infections have caused a wide spectrum of neurological diseases, such as Guillain–Barré syndrome, myelitis, meningoencephalitis, and congenital microcephaly. No effective therapies currently exist for treating patients infected with ZIKV. Herein, we evaluated the anti-viral activity of favipiravir (T-705) and ribavirin against Asian and African strains of ZIKV using different cell models, including human neuronal progenitor cells (hNPCs), human dermal fibroblasts (HDFs), human lung adenocarcinoma cells (A549) and Vero cells. Cells were treated with favipiravir or ribavirin and effects on ZIKV replication were determined using quantitative real-time PCR and plaque assay. Our results demonstrate that favipiravir or ribavirin treatment significantly inhibited ZIKV replication in a dose-dependent manner. Moreover, favipiravir treatment of ZIKV-infected hNPCs led to reduced cell death, enhanced AKT pathway phosphorylation, and increased expression of anti-apoptotic factor B cell lymphoma 2. In conclusion, our results demonstrate conclusively that favipiravir inhibits ZIKV replication and prevents cell death, and can be a promising intervention for ZIKV-associated disease. View Full-Text
Keywords: favipiravir; ribavirin; Zika virus; hNPCs; anti-viral favipiravir; ribavirin; Zika virus; hNPCs; anti-viral
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Kim, J.-A.; Seong, R.-K.; Kumar, M.; Shin, O.S. Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models. Viruses 2018, 10, 72.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top